C07AG02 carvedilol
CARDIOVASCULAR SYSTEM ›BETA BLOCKING AGENTS ›BETA BLOCKING AGENTS ›Alpha and beta blocking agents
健保收載品項 TFDA 在效許可證 22 FDA 已核准
台灣藥品與外觀
健保收載品名:"永信" 心通寧錠 25 毫克、"永信" 心通寧錠6.25毫克、佳地諾錠25毫克、優迪絡錠 6.25 毫克、卡心平錠 6.25 毫克、卡心平錠25毫克、卡菲蒂羅錠 12.5 毫克、卡菲蒂羅錠 25 毫克、卡菲蒂羅錠6.25毫克、壓落保錠25毫克、壓落敏錠 25 公絲、平鬱錠12.5毫克、心全錠 6.25毫克、心全錠25毫克、心達諾錠 25 毫克、怡心坦錠 25 毫克
無外觀照
壓落敏錠 25 公絲
無外觀照
卡心平錠25毫克
資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 高血壓、鬱血性心臟衰竭。
- 高血壓、鬱血症心臟衰竭。
美國 FDA 適應症(英文原文對照)
1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] .
資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。
健保給付規定
查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-07-01)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。